<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121164">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01525407</url>
  </required_header>
  <id_info>
    <org_study_id>2545.00</org_study_id>
    <secondary_id>NCI-2011-03827</secondary_id>
    <secondary_id>2545.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>R01HL108307</secondary_id>
    <nct_id>NCT01525407</nct_id>
  </id_info>
  <brief_title>Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation</brief_title>
  <official_title>Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies donor atorvastatin treatment for the prevention of severe acute
      graft-versus-host disease (GVHD) in patients undergoing myeloablative peripheral blood stem
      cell (PBSC) transplantation. Giving chemotherapy and total-body irradiation (TBI) before a
      donor PBSC transplant helps stop the growth of cancer cells. It may also prevent the
      patient's immune system reject the donor's stem cells. When the healthy stem cells from a
      donor are infused into the patient they may help the patient's bone marrow make stem cells,
      red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a
      donor can make an immune response against the body's normal cells. Giving atorvastatin to
      the donor before transplant may prevent this from happening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess whether 2 weeks of donor statin treatment reduces the risk of severe acute
      GVHD.

      SECONDARY OBJECTIVES:

      I. To assess whether 2 weeks of statin treatment of normal PBSC donors is feasible,
      tolerable and safe.

      OUTLINE:

      Donors receive atorvastatin orally (PO) beginning on day -14 and continuing until the last
      day of stem cell collection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade 3-4 acute GVHD</measure>
    <time_frame>First 100 days after transplant</time_frame>
    <description>A reduction in the cumulative incidence of acute GVHD from 15% to &lt; 5% would represent a reasonable goal after hematopoietic cell transplant (HCT) with filgrastim (G-CSF)-mobilized blood cells and constitute study success.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic extensive GVHD</measure>
    <time_frame>Up to 3 years after transplant</time_frame>
    <description>Will be assessed with the use of cumulative incidence plots. Will be assessed with the use of cumulative incidence plots.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>1 year after transplant</time_frame>
    <description>Evaluated as Kaplan-Meier estimate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grades II-IV acute GVHD</measure>
    <time_frame>First 100 days after transplant</time_frame>
    <description>Will be assessed with the use of cumulative incidence plots.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grades II-IV chronic GVHD</measure>
    <time_frame>Up to 3 years after transplant</time_frame>
    <description>Will be assessed with the use of cumulative incidence plots. Will be assessed with the use of cumulative incidence plots.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>At day 100</time_frame>
    <description>Will be assessed with the use of cumulative incidence plots.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>At 1 year after HCT</time_frame>
    <description>Will be assessed with the use of cumulative incidence plots.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year after transplant</time_frame>
    <description>Determined and presented as Kaplan-Meier estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of donors who have to discontinue atorvastatin because of toxicity</measure>
    <time_frame>Up to stem cell collection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring secondary systemic immunosuppressive therapy</measure>
    <time_frame>First 100 days after transplant</time_frame>
    <description>Will be assessed with the use of cumulative incidence plots.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent or progressive malignancy</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be assessed with the use of cumulative incidence plots.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Supportive care (donor statin treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donors receive atorvastatin calcium PO beginning on day -14 and continuing until the last day of stem cell collection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo myeloablative allogeneic PBSC transplant</description>
    <arm_group_label>Supportive care (donor statin treatment)</arm_group_label>
    <other_name>allogeneic stem cell transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin Calcium</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Supportive care (donor statin treatment)</arm_group_label>
    <other_name>CI-981</other_name>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo myeloablative allogeneic PBSC transplant</description>
    <arm_group_label>Supportive care (donor statin treatment)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Human leukocyte antigen (HLA)-identical sibling donor

          -  Myeloablative preparative regimen (i.e., &gt;= TBI 12.0 Gy, &gt;= busulfan (BU) 8.0 mg/kg
             PO, &gt;= BU 6.4 mg/kg intravenously (IV), &gt;= treosulfan 42 g/m^2 IV) according to
             investigational study or standard treatment plan; other &quot;myeloablative&quot; preparative
             regimens are acceptable as long as they are approved by the principal investigator or
             designee

          -  Transplantation of PBSC

          -  Cyclosporine (CSP)-based postgrafting immunosuppression

          -  Willingness to give informed consent

          -  DONOR: Age &gt;= 18 years

          -  DONOR: HLA genotypically identical sibling

          -  DONOR: Willingness to give informed consent

        Exclusion Criteria:

          -  Nonmyeloablative preparative regimen

          -  Participation in an investigational study that has acute GVHD as the primary endpoint

          -  The allogeneic PBSC donor has a contraindication to statin treatment

          -  DONOR: Age &lt; 18 years

          -  DONOR: Active liver disease (alanine aminotransferase [ALT] or aspartate
             aminotransferase [AST] levels &gt; 2 times the upper limit of normal [ULN])

          -  DONOR: History of myopathy

          -  DONOR: Hypersensitivity to atorvastatin

          -  DONOR: Pregnancy

          -  DONOR: Nursing mother

          -  DONOR: Current serious systemic illness

          -  DONOR: Concurrent treatment with strong inhibitors of hepatic cytochrome P450 (CYP)
             3A4 (i.e. clarithromycin, erythromycin, protease inhibitors, azole antifungals)

          -  DONOR: Current use of statin drug

          -  DONOR: Failure to meet Fred Hutchinson Cancer Research Center (FHCRC) or local
             criteria for stem cell donation

          -  DONOR: Total creatinine kinase &gt; 2 times the ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Mielcarek</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>February 26, 2016</lastchanged_date>
  <firstreceived_date>January 31, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
